Side-by-side · Research reference

DSIPvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BHuman-MechanisticDraft11/40 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

DSIP

Selank

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

—

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Selank

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

150–300 mcg / dose intranasalZaderej 2014

Frequency

Once daily, pre-sleep

2–3× per day during stress

Lower / starter dose

50 mcg pre-sleep

75 mcg / dose

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

8–12 weeks per cycle

10–14 day cycles, repeated as needed

Reconstitution

Bacteriostatic water

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

30–60 min pre-sleep

Morning + early afternoon preferred

Half-life

Short plasma; CNS effects last hours

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

DSIP

Selank

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

Limited Western RCT data

Pregnancy / OB

Avoid

Avoid — insufficient data

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

DSIP

Selank

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Injection site

SQ — abdomen. Rotate sites.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

30–60 min pre-sleep.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle

29–31G insulin syringe.

Avoid co-administration with strong sedatives or other anxiolytics initially.